Warfarin-Aspirin Symptomatic Intracranial Disease Study for Stroke

If you are a physician and want to know more about how to refer patients to the WASID study contact the principal investigator nearest you. Other questions may be sent to the study coordinator in your area.

Illustrated by David Uhl Courtesy of the National Stroke Association

Principal Investigator Study Design Study Criteria Criteria for Non-Invasive Test Inclusion and Exclusion Criteria Endpoints List of WASID Centers Links to Other Sources     WASID Emory Contact List (Password Protected)

                      Marc I. Chimowitz, MBChB
                      Department of Neurology
                      School of Medicine
                      Emory University
                      Atlanta, GA 30322

     Study Design

                      The main objective of this trial is to compare warfarin (target INR 2-3)
                      with aspirin (1300 mg/day) for preventing stroke (ischemic and
                      hemorrhagic) and vascular death in patients with symptomatic stenosis
                      of a major intracranial artery.  This is a prospective, randomized
                      double-blind, multi-center trial. The sample size required will be 403
                      patients per group

     Study Criteria

                      Patients with transient ischemic attack TIA or stroke caused by
                      angiographically proven stenosis of greater than or equal to 50
                      percent of a major intracranial artery will be randomized to warfarin
                      or aspirin therapy.    See inclusion and exclusion criteria

    Endpoints
                      The primary analysis will compare the rates of stroke (ischemic and
                      hemorrhagic) and vascular death in the two treatment groups.
                      Secondary analyses will compare the two treatment groups with
                      respect to rates of i) all vascular deaths and disabling stroke, ii) all
                     stroke (ischemic and hemorrhagic), iii) fatal and nonfatal ischemic
                      stroke, iv) all ischemic stroke, myocardial infarction and vascular
                      death, v) all major systemic and any intracranial hemorrhage, vi) all
                      ischemic stroke in the territory of the stenotic intracranial artery.  A
                      secondary analysis of  the patients in the "best medical therapy group",
                      will identify  the rate of ischemic stroke in the territory of the stenotic
                      intracranial artery.  Predictions are that the ischemic stroke rate will be
                      <3% per year in patients with 50%-69% intracranial stenosis and >  6%
                       per year in  patients with 70%-99% intracranial stenosis.

We are interested in your comments about this web site. Send email to: mlynn@sph.emory.edu